Latest Capital Efficiency News

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

Variscan Mines’ Scoping Study for the San José Mine restart in Spain reveals strong economics, low upfront capital, and an 11-year mine life, setting the stage for zinc and lead production from 2028.

Harmoney Corp Limited has reported a strong first half of 2026, surpassing previous full-year profits and upgrading its FY26 cash NPAT guidance to $13 million, driven by loan book growth and automation advances.

Brazilian Rare Earths Limited has secured a key Trial Mining Licence for its Monte Alto project, marking a significant step toward commercial rare earths production in Brazil.

Orora Limited updates its Dividend Reinvestment Plan price for the upcoming ordinary dividend, maintaining a steady payout amid evolving shareholder options.

Turners Automotive Group has unveiled an ambitious roadmap aiming for $100 million net profit before tax by FY31, driven by organic growth and strategic network expansion across its integrated used car platform.

Peppermint Innovation Limited reported a $1.27 million net loss for the half-year ending December 2025 while achieving key milestones including activation of national payment rails in the Philippines and settling a statutory demand that led to an ASX trading suspension.

Catalina Resources has secured a significant silver portfolio in Western Australia by acquiring Spinifex Silver Pty Ltd, adding a district-scale opportunity alongside its existing gold and copper assets.

GoldArc Resources has kicked off two major drilling campaigns at its Leonora South Gold Project, aiming to expand and de-risk its existing gold resource base through a strategic partnership and innovative funding model.

Lendlease Group has updated its dividend announcement, confirming the Dividend Reinvestment Plan price and detailing dividend amounts in Australian, New Zealand, and British currencies.

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.

OzAurum Resources has secured environmental approval for Stage 1 of its Mulgabbie North Gold Project, clearing a major regulatory hurdle and accelerating its path to near-term production.